Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,199.0
25.2 (0.79%)

 

  • STI Straits Times Index
    3,199.0
    25.2 (0.79%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,606.0
    7.7 (0.48%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,787.2
    377.5 (1.49%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,593.2
    25.0 (0.70%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,215.5
    190.1 (0.65%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,656.0
    -2.8 (-0.04%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,613.6M
  • Value: 1,230.2M
  • Rise: 192
  • Fall: 154
  • Unch: 405

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.081-0.001
Hatten Land0.073-0.005
Jiutian Chemical0.089-0.002
Shen Yao0.003-0.001
Rex Intl0.350+0.025
AusGroup0.029+0.003
Singtel2.550-
Sinjia Land0.052+0.005
Oceanus0.040-
Leader Env0.083+0.009

World Indices

World Indices
Name Last Change
Nasdaq 15,021.8 +124.5
HSI 25,787.2 +377.5
HSCEI 9,136.1 +164.7
Jakarta 6,656.0 -2.8
Nikkei 225 29,215.5 +190.1
SSE Comp 3,593.2 +25.0
Shanghai A 3,765.7 +26.2
Shanghai B 280.0 +0.7
KOSPI 3,029.0 +22.4

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Phapros Tbk. PT PHAPROS TBK
Quotes 10 Minutes Delayed. Updated at 19 Oct 2021 15:00
Last (IDR): 1,170.000 Change: +5.000 High: 1,195.000 Remarks: -
Change (%): +0.43 Low: 1,165.000
Open 1,165.000 Yesterday's Close 1165.000
Buy Price 1165.000 Sell Price 1170.000
Buy Volume ('000) 113.8 Sell Volume ('000) 2.1
Cumulative Volume ('000) 116.7 Cumulative Value 137,223,000
Click to show Stock Prices chart

Key Statistics

EPS (IDR) a 57.72365 Trailing EPS (IDR) e 82.71207 NAV (IDR) b 865.2471
PE a 20.269 Trailing PE f 14.145 Price / NAV b 1.3522
Dividend (IDR) d 23.089464 Cash In Hand (IDR) g 85.4138 Issued & Paid-up Shares c 840,000,000
Dividend Yield (%) d 1.973 Price / Cash In Hand g 13.698 Treasury Shares h -
Beta - 75 Daysi 0.011 R-Squared - 75 Days(%)i - Market Cap (M) 982,800.000
Beta - 500 Daysi 1.117 R-Squared - 500 Days (%)i 11.53 Enterprise Value (M) 1,906,039.137
Piotroski F Score 4 Exchange Code PEHA Par Value ( IDR ) 100.00000
52 Weeks Volatility (%) 51.11 6-Month VWAP 1254.149 Free Float (%) 34.2
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 27 Dec 2018.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 27 Dec 2018.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Phapros Tbk. IDX 982,800.000 20.269 14.145 1.3522 1.973
Industry Pharmaceuticals: Major IDX 5,640,471.751 72.748 50.675 2.1222 1.687
Local Peer Kimia Farma Tbk. IDX 13,551,760.002 768.291 508.240 1.9297 0.052
Local Peer Soho Global Health Tbk. IDX 6,472,767.000 37.609 28.419 2.9586 4.627
Local Peer Merck Tbk. IDX 1,554,560.000 21.620 12.813 2.2393 3.516
Global Peer JOHNSON & JOHNSON NYSE 421,512.698 28.647 23.724 6.0580 2.486
Global Peer PFIZER INC NYSE 231,668.431 24.092 17.513 3.3076 3.677
Global Peer ELI LILLY AND COMPANY NYSE 228,603.727 36.909 37.657 35.4733 1.239
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 200,450.143 24.685 22.287 3.7092 2.341
Global Peer MERCK & CO INC NYSE 195,295.196 27.635 35.056 5.8658 3.213
Global Peer ABBVIE INC NYSE 189,848.147 41.670 28.813 15.1044 4.500
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 183,696.428 57.477 48.713 11.7183 1.958
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 183,335.881 28.451 25.753 17.5356 1.301
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 126,526.943 - - 3.4375 3.263
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 121,368.928 8.646 17.526 1.6184 2.784
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC CO LTD (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), VIATRIS INC (NASDAQ), HANSOH PHARMACEUTICAL GROUP CO LTD (HKEx), INNOVENT BIOLOGICS INC (HKEx), REPLIGEN CORP (NASDAQ), CANSINO BIOLOGICS INC (HKEx), ORGANON & CO (NYSE), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), SINOPHARM GROUP CO. LTD. (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), CUREVAC NV (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), REMEGEN CO LTD (HKEx), ALLAKOS INC (NASDAQ), HUTCHMED (CHINA) LIMITED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), SHANGHAI PHARMACEUTICALS HOLDING CO (HKEx), HYGEIA HEALTHCARE HLDGS CO LTD (HKEx), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), AKESO INC (HKEx), SHANGHAI JUNSHI BIOSCIENCES CO LTD (HKEx), CHINA MEDICAL SYSTEM HLDGS LTD (HKEx), GUANGZHOU BAIYUNSHAN PHARMACEUTICAL (HKEx), INNOCARE PHARMA LTD (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), CHINA RESOURCES PHARMACEUTICAL GR (HKEx), NEKTAR THERAPEUTICS (NASDAQ), CHINA GRAND PHARMACEUTICAL & HEALTH (HKEx), CARSGEN THERAPEUTICS HLDGS LTD (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), SIMCERE PHARMACEUTICAL GRP LTD (HKEx), OPKO HEALTH INC (NASDAQ), CHINA TRADITIONAL CHINESE MED HLDGS (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), ERASCA INC (NASDAQ), ADC THERAPEUTICS SA (NYSE), QUANTERIX CORPORATION (NASDAQ), SHANGHAI HENLIUS BIOTECH INC (HKEx), IGM BIOSCIENCES INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), EVEREST MEDICINES LTD (HKEx), SHENZHEN HEPALINK PHARMACEUTICAL (HKEx), DICERNA PHARMACEUTICALS INC. (NASDAQ), SSY GROUP LIMITED (HKEx), CSTONE PHARMACEUTICALS (HKEx), OCUMENSION THERAPEUTICS (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), UNITED LABORATORIES INTL HLDGS LTD (HKEx), GENERATION BIO CO (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), ZYMEWORKS INC (NYSE), BEIJING TONG REN TANG CHINESE MEDIC (HKEx), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), IMMUNOTECH BIOPHARM LTD (HKEx), PROCAPS GROUP S A (NASDAQ), ABBISKO CAYMAN LTD (HKEx), GOSSAMER BIO INC (NASDAQ), SCICLONE PHARMACEUTICALS (HLDGS) LT (HKEx), KINNATE BIOPHARMA INC (NASDAQ), ICOSAVAX INC (NASDAQ), KRONOS BIO INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), CK LIFE SCIENCES INTL HLDG (HKEx), FULCRUM THERAPEUTICS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ANTENGENE CORP LTD (HKEx), KEROS THERAPEUTICS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), GH RESEARCH PLC (NASDAQ), ANNEXON INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), PETIQ INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), CHINA SHINEWAY PHARMACEUTICAL GR (HKEx), TRANSCENTA HOLDING LTD (HKEx), ALIGOS THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), GRITSTONE BIO INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), HUA MEDICINE (HKEx), SIGA TECHNOLOGIES INC (NASDAQ), PHARVARIS NV (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), ZHAOKE OPHTHALMOLOGY LTD (HKEx), BOLT BIOTHERAPEUTICS INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), AC IMMUNE SA (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), IGBB (Bursa), EVOLUS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), MINK THERAPEUTICS INC (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), CLENE INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), ESSA PHARMA INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), 89BIO INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), RACE ONCOLOGY LTD (ASX), VERRICA PHARMACEUTICALS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), TOT BIOPHARM INTL CO LTD (HKEx), EYEPOINT PHARMACEUTICALS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), DAWNRAYS PHARMACEUTICAL HLDGS (HKEx), CLEARSIDE BIOMEDICAL INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), CYBIN INC (NYSE American), CITIUS PHARMACEUTICALS INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), ATHENEX INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), BSTEAD (Bursa), NEXIMMUNE INC (NASDAQ), HARROW HEALTH INC (NASDAQ), FUSEN PHARMACEUTICAL CO LTD (HKEx), XOMA CORP (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), DURECT CORP (NASDAQ), PHARMA (Bursa), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), VINCERX PHARMA INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), ANNOVIS BIO INC (NYSE American), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), GAMIDA CELL LTD (NASDAQ), TRICIDA INC (NASDAQ), OBSEVA SA (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), IMMUNIC INC (NASDAQ), INOZYME PHARMA INC (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), MUSTANG BIO INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), IP (SET), ONCTERNAL THERAPEUTICS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), CHINA BIOTECH SERVICES HLDGS LTD (HKEx), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), EYENOVIA INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), NOVAN INC (NASDAQ), POLYPID LTD (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), IX Biopharma (SGX), ETON PHARMACEUTICALS INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), ZHONGZHI PHARMACEUTICAL HLDGS LTD (HKEx), NOXOPHARM LTD (ASX), KALA PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), ODONATE THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), KOTRA (Bursa), LANTERN PHARMA INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), LANNETT CO INC (NYSE), IMARA INC (NASDAQ), CRESO PHARMA LTD (ASX), TEMPEST THERAPEUTICS INC (NASDAQ), CHARMACY PHARMACEUTICAL CO LTD (HKEx), APTORUM GROUP LIMITED (NASDAQ), MEDIWOUND LTD (NASDAQ), NEW RAY MEDICINE INTL HLDG LTD (HKEx), AILERON THERAPEUTICS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), GALECTO INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), MANNATECH INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), PAK FAH YEOW INTERNATIONAL (HKEx), NOVA (Bursa), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), Hyphens Pharma (SGX), NEW CENTURY HEALTHCARE HLDGS CO LTD (HKEx), SANAI HEALTH INDUSTRY GP CO LTD (HKEx), EXOPHARM LTD (ASX), ABVC BIOPHARMA INC (NASDAQ), INVION LTD (ASX), VYNE THERAPEUTICS INC (NASDAQ), BIOHLDG (Bursa), VIRPAX PHARMA INC (NASDAQ), MODERN CHINESE MEDICINE GRP CO LTD (HKEx), WAI YUEN TONG MEDICINE HOLDINGS LTD (HKEx), SHENZHEN NEPTUNUS INTERLONG BIO-TEC (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), RENOVORX INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), BONE BIOLOGICS CORP (NASDAQ), BAUDAX BIO INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), SEQLL INC (NASDAQ), PURAPHARM CORPORATION LIMITED (HKEx), VALLON PHARMACEUTICALS INC (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), VIRIOS THERAPEUTICS INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), PHARMAXIS (ASX), XORTX THERAPEUTICS INC (NASDAQ), DERMATA THERAPEUTICS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), PALLA PHARMA LTD (ASX), AGEX THERAPEUTICS INC (NYSE American), ACER THERAPEUTICS INC (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), JCT (SET), EXTRAWELL PHARMACEUTICAL HLDGS (HKEx), NLS PHARMACEUTICS LTD (NASDAQ), SUNZEN (Bursa), HOTH THERAPEUTICS INC (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), ONCOSIL MEDICAL LIMITED (ASX), TREVI THERAPEUTICS INC (NASDAQ), ACRUX (ASX), IMMURON LIMITED (ASX), AVENUE THERAPEUTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), TALI DIGITAL LIMITED (ASX), NANJING SINOLIFE UNITED COMPANY LTD (HKEx), ISLAND PHARMACEUTICALS LTD (ASX), SUDA PHARMACEUTICALS LTD (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), PA SHUN INTERNATIONAL HOLDINGS LTD (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+5.000
+0.43 %
10 Days ---
20 Days ---
Medium Term Return 3 Months --20.000
-1.68 %
6 Months 23.089-80.000
-4.55 %
1 Year 23.089-485.000
-27.91 %
Long Term Return 2 Years 13372.799-95.000
+1049.63 %
Annualised Return Annualised --
+239.06 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 1,085.000 - 2,970.000 Change From 1 Year Low +85.000 % Change From 1 Year Low (%) +7.83
Change From 1 Year High -1800.000 % Change From 1 Year High (%) -60.61
2 Years Range 655.000 - 2,970.000 Change From 2 Years Low +515.000 % Change From 2 Years Low (%) +78.63
Change From 2 Years High -1800.000 % Change From 2 Years High (%) -60.61
5 Years Range 655.000 - 3,650.000 Change From 5 Years Low +515.000 % Change From 5 Years Low (%) +78.63
Change From 5 Years High -2480.000 % Change From 5 Years High (%) -67.95
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

PT Phapros Tbk is a pharmaceutical company, which is engaged in the production and marketing of pharmaceutical products. The firm's segments include OTC (Over The Counter), Toll-in, Ethical and OGB (generic drugs bearing). The company was founded on June 21, 1954 and is headquartered in Jakarta, Indonesia.

Historical Price Data

Date Open High Low Close Volume VWAP
19 Oct 2021 1165.000 1195.000 1165.000 1170.000 116,700 1175.8612
18 Oct 2021 1165.000 1175.000 1160.000 1165.000 199,000 1165.5578
15 Oct 2021 1170.000 1170.000 1160.000 1165.000 100,600 1163.0666
14 Oct 2021 1165.000 1175.000 1165.000 1170.000 127,700 1166.8168
13 Oct 2021 1175.000 1175.000 1165.000 1165.000 145,400 1167.6204
12 Oct 2021 1170.000 1175.000 1160.000 1175.000 205,900 1163.9169
11 Oct 2021 1170.000 1180.000 1160.000 1165.000 163,100 1164.2520
08 Oct 2021 1170.000 1170.000 1160.000 1160.000 281,500 1162.5311
07 Oct 2021 1165.000 1195.000 1160.000 1160.000 819,100 1174.7271
06 Oct 2021 1165.000 1165.000 1160.000 1160.000 130,900 1161.8182
05 Oct 2021 1170.000 1170.000 1160.000 1160.000 220,200 1162.5272
04 Oct 2021 1170.000 1170.000 1160.000 1170.000 202,700 1164.9408
01 Oct 2021 1160.000 1175.000 1155.000 1165.000 149,300 1165.1507
30 Sep 2021 1170.000 1190.000 1155.000 1165.000 395,100 1163.6269
29 Sep 2021 1160.000 1195.000 1150.000 1170.000 313,700 1168.0491
28 Sep 2021 1160.000 1160.000 1160.000 1160.000 425,900 1160.0000
27 Sep 2021 1160.000 1165.000 1155.000 1160.000 237,000 1158.6498
24 Sep 2021 1160.000 1170.000 1160.000 1160.000 123,200 1162.2281
23 Sep 2021 1170.000 1170.000 1160.000 1165.000 71,400 1165.1961
22 Sep 2021 1165.000 1170.000 1155.000 1170.000 124,700 1157.4900
21 Sep 2021 1160.000 1170.000 1155.000 1165.000 285,700 1159.2405
20 Sep 2021 1165.000 1170.000 1160.000 1170.000 85,300 1166.2368
Summary
Current 2 Weeks
(06 Oct 2021 to 19 Oct 2021)
1165.000 1195.000 1160.000 1170.000 2,289,900 -
Previous 2 Weeks
(22 Sep 2021 to 05 Oct 2021)
1165.000 1195.000 1155.000 1160.000 2,263,200 -
4 Weeks from
(25 Aug 2021 to 21 Sep 2021)
1160.000 1195.000 1155.000 1165.000 3,907,500 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.